Associate professor of medicine, McMaster University (MU), MU Medical Center Hemophilia Clinic, and Thrombosis Clinic at the Juravinski Hospital

Davide Matino, MD

Matino discussed data from the phase 3 BASIS study evaluating the recently approved Hympavzi.

Davide Matino, MD, MSc: Bringing Marstacimab Treatment to Hemophilia A and B 

Marstacimab (Hympavzi; Pfizer) decreased the total number of bleeds and the severity of bleeds in treated patients with hemophilia A or B without inhibitors.

These findings, from the phase 3 BASIS study, were presented at the

 66th American Society of Hematology (ASH) Annual Meeting and Exposition

, held December 7-10, 2024, in San Diego, California, by Davide Matino, MD, associate professor of medicine, McMaster University (MU), MU Medical Center Hemophilia Clinic, and Thrombosis Clinic at the Juravinski Hospital.

Marstacimab is an anti-tissue factor pathway inhibitor that was approved by the FDA in October for preventing or reducing bleeding episodes in patients with hemophilia A and B.

 The therapy is given weekly by an autoinjector pen and is the first subcutaneous option for those with hemophilia B in the United States. The ongoing BASIS is evaluating marstacimab in patients between the ages of 12 and 75 with severe hemophilia A or moderately severe to severe hemophilia B.

“Each one of these new therapies could have a very specific space because of their very peculiar characteristics, mode of action, or in reducing the burden of the treatment for some patients, or because of the specific needs of some patients. So, I think it's this evolution. I think it's very welcome for both the from both the treaters perspective and the patient's perspective,” Matino told 

® during the meeting, commenting on recent approvals of novel therapies for both hemophilia A and B.

Matino D, Gould T, Teeter J, Taylor CT, McDonald R, Palladino A. Descriptive Characterization of Bleeding Events in Participants with Severe Hemophilia Α or B without Inhibitors, Receiving Prophylactic Marstacimab Treatment. Presented at: ASH 2024 Annual Meeting. December 7-10, 2024; San Diego, CA. Abstract 716

U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors. News release. Pfizer. October 11, 2024. Accessed October 11, 2024. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-hympavzitm-marstacimab-hncq

Davide Matino, MD

Articles